A Phase 3 interventional study of Exercise, nutritional and pharmaceutical counceling and Nutritional and pharmaceutical counceling in Chagas Disease and Chagas Cardiomyopathy, sponsored by Evandro Chagas National Institute of Infectious Disease. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-27.
Sponsored by Evandro Chagas National Institute of Infectious Disease · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Chagas Cardiomyopathy with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Chagas Cardiomyopathy · Brazil.
Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 9th registered.
17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.
Browse Chagas Cardiomyopathy studies →2 of the 14 studies in Chagas Cardiomyopathy with a site in Brazil are open now. Recruiting first, the newest first:
InCor Heart Institute · Sites in Brazil
Ages 18–75
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 2 Chagas Cardiomyopathy studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 4 · Phase 4 2
First in 1995; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 45 across 13 interventional studies indexed under Chagas Cardiomyopathy.
Median enrollment 42 across the 11 interventional studies, 100 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 9 most frequent:
Evandro Chagas National Institute of Infectious Disease is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Evandro Chagas National Institute of Infectious Disease has 2 studies filed under Chagas Cardiomyopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this investigation is to evaluate the impact of exercise in a cardiac rehabilitation program on functional capacity, clinical markers, quality of life and biomarkers in patients with chronic chagasic cardiomyopathy.
The present study consisted in a randomized clinical study conducted at the Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro, Brazil. INI is a national reference center for treatment and research in infectious diseases and tropical medicine in Brazil, which follows a large cohort of patients with Chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the study are randomly divided in two groups: intervention and control groups. Safety analysis will be performed by monitoring any symptoms presented during data collection and follow-up study.
One of the potential risks that the patient may experience during the study is a noninvasive test that will be performed on a treadmill in a controlled environment, with the possibility of the appearance of symptoms such as fatigue, dyspnea, chest pain, dizziness, with minimal chances of occurring complications of difficult clinical control. Except for the blood test and the cardiopulmonary exercise test, the other tests to be performed are non-invasive and do not bring any risk to the participant's health. Will be collect 10 ml of blood which will be stored for up to five years for biomarker assessments.
During the exercise sessions, patients will be clinically monitored for decompensation, need for hospitalization and suspend or end the participation on the study. All cases will be individually assessed to determine the reversibility of the clinical status. Those cases will continue to be followed by the assistant staff, offering all the clinical support available in INI.
17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.
This study's enrollment of 30 is below the median of 45 across 13 interventional studies indexed under Chagas Cardiomyopathy.
Browse Chagas Cardiomyopathy studies →Evandro Chagas National Institute of Infectious Disease is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Compared within Chagas Cardiomyopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chagas Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: (1) Chagas disease diagnosis by serology; (2) chronic chagasic cardiomyopathy, with \<45% or compensated heart failure (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical treatment and (5) age above 18 years.
Exclusion Criteria: (1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4) evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise practice or hemodynamic stress tests (6) unavailability to attend three times a week for a minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.
Behavioral: Exercise, nutritional and pharmaceutical counceling
This arm will have only the counseling from pharmaceutical and nutritional professionals.
Behavioral: Nutritional and pharmaceutical counceling
The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
Functional capacity measured by peak exercise oxygen consumption
This measure is taken during a maximal progressive cardiopulmonary exercise test.
Time frame: Changes from baselint at three and six months
Muscle respiratory strength
Maximal inspiratory pressure and maximal expiratory pressure (cmH2O)
Time frame: Changes from baselint at three and six months
Body composition (body fat percentage)
Measurement of skinfold thickness were taken at the chest, midaxillary, triceps, subscapular, abdomen, suprailiac and thigh sites on the right side of the body while standing in a relaxed position. The sum of these seven skinfold thicknesses was used to estimate body composition by Jackson \& Pollock equation.
Time frame: Changes from baselint at three and six months
Cardiac function (maily ejection fraction)
Meaured by echocardiography
Time frame: Changes from baselint at three and six months
Laboratorial biomarkers composite
Total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol,triacylglycerol, glucose, glycated hemoglobin, inflammatory cytokines, Brain Natriuretic Peptide and components of oxidative stress.
Time frame: Changes from baselint at three and six months
Quality of life
Minnesota Living with Heart Failure questionnaire (MLHFQ). Score ranging from 0 - 105.
Time frame: Changes from baselint at three and six months
24 hours Holter
Cardiac rhythm through continuous dynamic ECG
Time frame: Changes from baselint at three and six months
Nutritional assessment
By semiquantitative food frequency questionnaire and 24-hour food intake recall.
Time frame: Changes from baselint at three and six months
Pharmaceutical assessment
Semi-structured questionnaires, Morisky´s test, Naranjo Algorithm.
Time frame: Changes from baselint at three and six months
Microvascular reactivity
Measured by laser speckle flowmetry
Time frame: Changes from baselint at three and six months
Body mass index
Measured by the body weight (kg) divided by squared height (in meters).
Time frame: Changes from baselint at three and six months
Ran from Mar 2015 to primary completion in Jan 2017, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evandro Chagas National Institute of Infectious Disease